Induction of caspase-dependent cellular apoptosis, inhibition of hepatocellular carcinoma development via IL-6/Jak2/IL-10 pathways, and reshaping of the immunosuppressive microenvironment using combined doxorubicin nanoparticles. This strategy enhances immune-stimulatory cytokines IFNγ, TNFα, and IL-12, and diminishes immunosuppressive cytokines CCL2, TGFβ, IL-4, IL-6, and IL-10. The gene discussed is CCL2; the disease is hepatocellular carcinoma.